Anti-CSF3R / G-CSFR Reference Antibody (CSL patent anti-G-CSFR)
Recombinant Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| FC, E, FTA |
---|---|
Primary Accession | Q99062 |
Reactivity | Cynomolgus, Human, Mouse |
Clonality | Monoclonal |
Isotype | IgG4 |
Calculated MW | 150 KDa |
Target/Specificity | CSF3R / G-CSFR |
---|---|
Endotoxin | < 0.001EU/ µg,determined by LAL method. |
Conjugation | Unconjugated |
Expression system | CHO Cell |
Format | Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column. |
Name | CSF3R |
---|---|
Synonyms | GCSFR |
Function | Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differentiation and survival of cells along the neutrophilic lineage. In addition it may function in some adhesion or recognition events at the cell surface. |
Cellular Location | [Isoform 2]: Secreted. |
Tissue Location | One or several isoforms have been found in myelogenous leukemia cell line KG-1, leukemia U-937 cell line, in bone marrow cells, placenta, and peripheral blood granulocytes. Isoform GCSFR-2 is found only in leukemia U-937 cells. Isoform GCSFR-3 is highly expressed in placenta |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.